Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Approval of tisa-cel for follicular lymphoma

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, comments on the recent approval of tisagenlecleucel (tisa-cel) for follicular lymphoma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.